Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

The FDA issued a Complete Response Letter for Summits ivonescimab application in post-TKI EGFR-mutated lung cancer, saying the evidence did not establish a statistically significant overall-survival benefit; traders are reacting to the setback and debating whether it undermines the broader drug thesis. Bearish voices see a major regulatory blow, while bullish traders argue the decision is limited to this indication and are focused on future trials, especially HARMONi-3.

Helus Pharmas Phase 3 APPROACH topline readout for HLP003 in major depressive disorder is the dominant focus, with traders treating the results as a high-stakes catalyst. Bullish investors cite the adjunctive design and potential for shorter clinic sessions, while others are wary of disappointing data and dilution; unverified claims about the results remain speculation.

Positive interim results from Alpha Taus REGAIN trial in recurrent glioblastoma are driving attention: all treated patients were reported alive, with objective responses in the six evaluable patients. Traders are enthusiastic about the early signal and its potential implications, while some stress that the small cohort needs longer follow-up to clarify durability and safety.

A sharp LUNC move and reported pickup in trading volume have renewed attention, with traders pointing to token burns, the anticipated Market Module 2.0 rollout, and speculation that litigation could lead to a large supply reduction. Bulls see these as potential catalysts, while skeptics argue that the huge supply and weak activity limit the impact of burns.

Speculation that Nvidia CEO Jensen Huang could return is driving hopes for a broader tech-led rebound, with traders also watching Nvidia earnings and the Anthropic IPO. Others doubt the comeback rumor and point to market weakness, macro risks, and volatility as reasons for caution.

Traders are debating whether enterprise AI will create implementation work for Accenture or weaken its traditional consulting model, with concerns that clients are pausing projects when returns are unclear and leaving consultants underused. Some see the AI-disruption fears as overdone and point to valuation as support, but the discussion is dominated by uncertainty over client demand and billable work.

KOLD is moving amid volatile natural-gas trading, with traders pointing to warm-weather expectations, ample storage and strong production as bearish pressures on gas prices. Some see KOLDs strength as a response to that bearish setup, while others warn that forecast cold snaps and crowded short positions could trigger a natural-gas squeeze and reverse the move.

A report that Samsung is in talks to acquire Modine has driven a sharp share-price surge, but no deal or terms have been confirmed. Traders are divided over whether the takeover speculation justifies further gains or whether the stock could retreat, with some also citing margin pressure and cash use in Modines data-center expansion.

XRPs steep drop below the psychologically important $1 level amid a broader crypto selloff is dominating discussion, with traders pointing to Bitcoin weakness and liquidations. The community is split between calling the move capitulation and buying the dip, and expecting further losses amid concerns about weak momentum and limited catalysts.

BioNTech is drawing attention after quarterly results topped estimates and the company raised its full-year revenue outlook, while traders focus on oncology progressespecially pumitamigas it shifts beyond COVID vaccines. Bulls see promise in the pipeline, while skeptics question clinical execution and compare its progress unfavorably with Moderna.